Logo

Agendia Joins Personalized Medicine Coalition

Sep 26, 2007
NEW YORK (GenomeWeb News) - Dutch diagnostics maker Agendia said today it has joined the Personalized Medicine Coalition, a consortium focused on public policy and regulatory issues related to the adoption of personalized medicine.
 
Agendia makes MammaPrint, an in vitro diagnostic multivariate index assay for breast cancer recurrence that was the first such test to be cleared by the US Food and Drug Administration.
 
Now that the Amsterdam-based firm is marketing the test in the US, "we believe it is now time to actively participate in the discussion about the implementation of personalized medicine in the US," company CEO Bernhard Sixt said in a statement.
Breaking News
The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.